Importance

Loading Importance Indicators...

Abstract

Compounds of formula I: ##STR1## wherein A is a heterocycle containing a nitrogen atom and optionally saturated or unsaturated and optionally further substituted by an oxo group (.dbd.O); R is: hydrogen, cyano, (C.sub.1-4)alkoxycarbonyl, carbamoyl; optionally substituted (C.sub.4-7)-cycloalkyl, aryl or heterocycle; (C.sub.1-8)alkyl, (C.sub.2-8)alkenyl or (C.sub.2-8)alkynyl optionally branched and/or substituted by (C.sub.4-7) cycloalkyl, aryl or heterocycle; aryloxy, heterocyclyloxy, aryl(C.sub.1-4)alkoxy, heterocyclyl(C.sub.1-4)alkoxy, amino substituted by one or two (C.sub.1-4)alkyl group(s), aryl-amino, heterocyclyl-amino, aryl(C.sub.1-4)alkyl-amino, or heterocyclyl(C.sub.1-4)alkylamino; Y is methylene or ethylene; W is an optionally substituted aryl or heterocycle; R.sub.1 is hydrogen, (C.sub.4-7)cycloalkyl or a (C.sub.2-8)alkyl, (C.sub.2-8)alkenyl or (C.sub.2-8)alkynyl group optionally substituted by hydroxy, oxo, (C.sub.4-7)cycloalkyl, aryl or heterocycle, and optionally interrupted by one or more heteroatom(s) or heterogroup(s); R.sub.2 is a (C.sub.1-6)alkyl or polyfluoro(C.sub.1-6)alkyl group; the N.fwdarw.O derivatives of the compounds of formula I and the pharmaceutically acceptable salts thereof. The compounds of formula (I) are PDE 4 inhibitors and may be used in compositions and methods involving PDE 4 inhibition.

Loading the Abstract Image...

First Claim